10-Q: Bone Biologics Reports Q2 2024 Results, Progresses Clinical Trial
Quarterly Report
Bone Biologics Corporation announced its second quarter 2024 financial results, highlighting a decrease in operating expenses and the commencement of a pilot clinical study for its NB1 bone graft device.
Summary
- Bone Biologics Corporation reported its financial results for the second quarter of 2024, showing a net loss of $783,733, or $0.67 per share, compared to a net loss of $1,769,238, or $5.21 per share, for the same period in 2023.
- The company's research and development expenses decreased significantly to $350,442 for the three months ended June 30, 2024, from $2,295,251 for the same period in 2023, due to reduced spending on NELL-1 protein production.
- General and administrative expenses also decreased to $459,223 from $744,617 year-over-year, primarily due to lower legal costs.
- For the six months ended June 30, 2024, the net loss was $1,649,703, or $1.80 per share, compared to a net loss of $5,479,137, or $18.57 per share, for the same period in 2023.
- The company's cash balance was $2,332,068 as of June 30, 2024, and they received approximately $1.7 million in net proceeds from a warrant inducement transaction in August 2024.
- Bone Biologics has commenced a pilot clinical study for its NB1 bone graft device, with the first two patients treated in Australia.
- The company estimates operating expenditures of $5.1 million for the next twelve months and anticipates needing approximately $5 million to complete first-in-man studies and an additional $24 million for FDA approval for a spine interbody fusion indication.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there are positive developments such as the start of a clinical trial and reduced losses, the company's financial situation remains precarious with a going concern warning and reliance on future capital raises. The sentiment is therefore cautiously negative.
Positives
- The company's net loss decreased significantly year-over-year for both the three and six month periods ending June 30, 2024.
- Research and development expenses decreased substantially due to reduced spending on NELL-1 protein production.
- General and administrative expenses decreased due to lower legal costs.
- The company successfully raised additional capital through a warrant inducement transaction.
- The pilot clinical study for the NB1 bone graft device has commenced with the first two patients treated.
Negatives
- The company continues to operate at a loss, with a net loss of $783,733 for the three months ended June 30, 2024.
- The company has an accumulated loss of approximately $82.6 million since inception.
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company is dependent on raising additional capital to fund its operations.
- There is no assurance that the company will be able to obtain sufficient financing to meet its needs.
Risks
- The company's ability to continue as a going concern is uncertain due to its history of losses and need for additional financing.
- The company's success depends on obtaining regulatory approval for its products, which is not guaranteed.
- The company relies on third-party manufacturers for its drug products, which could lead to supply chain issues.
- The company is subject to extensive regulation by governmental authorities.
- The company's patents and licenses could be challenged, invalidated, or circumvented.
- The company is obligated to make significant milestone payments to UCLA TDG.
- The company is subject to risks related to clinical trials, which could be delayed or suspended.
Future Outlook
The company anticipates continued investment in development activities for NELL-1 as they prepare for a pivotal clinical study and estimates operating expenditures of $5.1 million for the next twelve months. They also anticipate needing approximately $5 million to complete first-in-man studies, and an estimated additional $24 million in scientific expenses to achieve FDA approval for a spine interbody fusion indication.
Management Comments
- The company is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1.
- The company believes its platform technology has application in delivering improved outcomes in various surgical specialties.
- The company is diligently proceeding with developing and commercializing licensed products under UCLA TDG patents.
- The company will continue to attempt to raise additional debt and/or equity financing to fund future operations.
Industry Context
Bone Biologics is operating in the competitive orthopedic market, specifically targeting the spinal fusion segment. The company's focus on NELL-1 technology and its potential for improved bone regeneration positions it within the broader trend of developing advanced biologics for surgical applications. The company's progress in clinical trials and regulatory interactions will be closely watched by competitors and investors in the space.
Comparison to Industry Standards
- Bone Biologics is a development-stage company, and its financial results are not directly comparable to established medical device companies with commercialized products.
- Companies like Medtronic, Stryker, and Johnson & Johnson have significant revenue streams from their existing product portfolios, while Bone Biologics is still in the clinical development phase.
- The company's research and development spending is typical for a biotech company at this stage, but the decrease in spending in 2024 is notable and may reflect a shift in priorities or a need to conserve cash.
- The company's reliance on external funding is common for early-stage biotech companies, but the uncertainty around future financing is a significant risk.
- The company's progress in clinical trials will be a key factor in determining its future success and valuation, and will be compared to other companies developing similar technologies.
Stakeholder Impact
- Shareholders face the risk of dilution from future equity financing.
- Employees are subject to the uncertainty of the company's financial stability.
- Customers (surgeons and patients) may benefit from the potential of the company's products if they are successfully commercialized.
- Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
Next Steps
- The company will continue to develop and commercialize licensed products under UCLA TDG patents.
- The company will continue to attempt to raise additional debt and/or equity financing.
- The company will continue the pilot clinical study of the NB1 bone graft device.
- The company will prepare for a pivotal clinical study in the future.
Key Dates
| Date | Description |
|---|---|
| 2004-09-09 | Bone Biologics, Inc. was incorporated in California. |
| 2006-03-15 | Effective date of the original Exclusive License Agreement between the Company and UCLA TDG. |
| 2007-10-18 | Bone Biologics Corporation was incorporated in Delaware as AFH Acquisition X, Inc. |
| 2014-09-19 | Merger Agreement between the Company, its subsidiary, and Bone Biologics, Inc. |
| 2014-09-22 | The Company changed its name to Bone Biologics Corporation. |
| 2016-12-22 | Date after which UCLA TDG can exercise a payment election related to a Liquidity Event. |
| 2017-06-19 | Date of the Amended and Restated Exclusive License Agreement between the Company and UCLA TDG. |
| 2019-03-21 | Date of the Amended and Restated Exclusive License Agreement with UCLA TDG. |
| 2019-04-09 | Effective date of the Amended and Restated Exclusive License Agreement with UCLA TDG. |
| 2022-10 | The company completed a public equity offering, which included the issuance of warrants. |
| 2023-05-01 | The company's stockholders authorized a 1-for-30 reverse stock split. |
| 2023-06-05 | The company filed an amendment to effect a 1-for-30 reverse stock split. |
| 2023-12-12 | The company's stockholders authorized a 1-for-8 reverse stock split. |
| 2023-12-14 | The company filed an amendment to effect a 1-for-8 reverse stock split. |
| 2023-12-20 | Effective date of the 1-for-8 reverse stock split. |
| 2024-03-06 | The company sold common stock and warrants in a public offering. |
| 2024-06-20 | The company announced the first patient was treated in the pilot clinical study. |
| 2024-06-30 | End of the reporting period for the quarterly report. |
| 2024-08-01 | The company entered into warrant inducement letter agreements. |
| 2024-08-02 | The company completed the warrant inducement transaction. |
| 2024-08-06 | 264,938 Abeyance Shares were released and issued. |
| 2024-08-09 | Date of the quarterly report. |
Keywords
NELL-1, bone regeneration, spinal fusion, medical device, clinical trial, FDA approval, warrant inducement, financial results, NB1 bone graft, UCLA TDG
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.